Frequency Therapeutics Company Leadership
| KRRO Stock | 12.72 0.15 1.19% |
About 75% of Frequency Therapeutics' corporate insiders are selling. The analysis of the overall insider sentiment regarding Frequency Therapeutics suggests that many insiders are alarmed. Frequency Therapeutics employs about 87 people. The company is managed by 21 executives with a total tenure of roughly 203 years, averaging almost 9.0 years of service per executive, having 4.14 employees per reported executive.
Insider Sentiment 25
Mostly Selling
Selling | Buying |
Latest Trades
| 2024-11-11 | Vineet Agarwal | Disposed 800 @ 70 | View | ||
| 2024-10-17 | Vineet Agarwal | Disposed 10216 @ 78.26 | View | ||
| 2024-04-22 | Venture Opportunity Fund Atlas | Acquired 17857 @ 56 | View | ||
| 2023-11-22 | David L Lucchino | Disposed 1156 @ 37.69 | View |
Monitoring Frequency Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Frequency | Build AI portfolio with Frequency Stock |
Frequency Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2916) % which means that it has lost $0.2916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6346) %, meaning that it created substantial loss on money invested by shareholders. Frequency Therapeutics' management efficiency ratios could be used to measure how well Frequency Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 10th of February 2026, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to drop to -0.41. At this time, Frequency Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 10th of February 2026, Non Currrent Assets Other is likely to grow to about 7.5 M, while Total Assets are likely to drop about 173.2 M.As of the 10th of February 2026, Common Stock Shares Outstanding is likely to grow to about 10.8 MThe majority of Frequency Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Frequency Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Frequency Therapeutics. Please pay attention to any change in the institutional holdings of Frequency Therapeutics as this could imply that something significant has changed or is about to change at the company.
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 9.4 M | Current Value 9.4 M | Avarage Shares Outstanding 4.3 M | Quarterly Volatility 3.8 M |
Frequency Therapeutics Workforce Comparison
Frequency Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,097. Frequency Therapeutics holds roughly 87.0 in number of employees claiming about 8% of equities under Health Care industry.
Frequency Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Frequency Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Frequency Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Frequency Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cerio Jeffrey over a month ago Acquisition by Cerio Jeffrey of 41902 shares of Frequency Therapeutics subject to Rule 16b-3 | ||
Oliver Dolan over a month ago Acquisition by Oliver Dolan of 21482 shares of Frequency Therapeutics subject to Rule 16b-3 | ||
Pearson Timothy R over six months ago Acquisition by Pearson Timothy R of 6010 shares of Frequency Therapeutics at 14.87 subject to Rule 16b-3 | ||
Loic Vincent over six months ago Insider Trading | ||
Oliver Dolan over six months ago Insider Trading | ||
Olugemo Olukemi over a year ago Acquisition by Olugemo Olukemi of 42000 shares of Frequency Therapeutics at 33.5 subject to Rule 16b-3 | ||
Agarwal Vineet over a year ago Disposition of 164 shares by Agarwal Vineet of Frequency Therapeutics at 73.7116 subject to Rule 16b-3 | ||
Behbahani Ali over a year ago Acquisition by Behbahani Ali of 17857 shares of Frequency Therapeutics at 56.0 subject to Rule 16b-3 |
Frequency Therapeutics Notable Stakeholders
A Frequency Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Frequency Therapeutics often face trade-offs trying to please all of them. Frequency Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Frequency Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andrew Fraley | CoFounder Advisor | Profile | |
| Joshua Rosenthal | CoFounder Advisor | Profile | |
| Josh Rosenthal | CoFounder Advisor | Profile | |
| Ram MBA | President, CEO | Profile | |
| Nessan Bermingham | CoFounder Chairman | Profile | |
| MBA MD | CoFounder Director | Profile | |
| Marco Passini | VP biology | Profile | |
| Shelby JD | Senior Counsel | Profile | |
| Loic Vincent | Chief Officer | Profile | |
| Vineet MBA | Chief Officer | Profile | |
| Ravi Ramadas | Vice Development | Profile | |
| Oliver Dolan | Interim Officer | Profile | |
| Steven Colletti | Chief Officer | Profile | |
| Todd MBA | Chief Officer | Profile | |
| Venkat Krishnamurthy | Senior Platform | Profile | |
| Stephanie Engels | Senior Culture | Profile | |
| Gaozhong Zhu | Manufacturing Chemistry | Profile | |
| Todd Chappell | Chief Officer | Profile | |
| PharmD JD | Senior Counsel | Profile | |
| Kemi MD | Chief Officer | Profile | |
| Olukemi MD | Advisor | Profile |
About Frequency Therapeutics Management Performance
The success or failure of an entity such as Frequency Therapeutics often depends on how effective the management is. Frequency Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Frequency management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Frequency management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.60) | (0.57) |
Frequency Therapeutics Workforce Analysis
Traditionally, organizations such as Frequency Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Frequency Therapeutics within its industry.Frequency Therapeutics Manpower Efficiency
Return on Frequency Therapeutics Manpower
| Revenue Per Employee | 26.1K | |
| Revenue Per Executive | 108.1K | |
| Net Loss Per Employee | 960.7K | |
| Net Loss Per Executive | 4M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 5.6M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Frequency Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Biotechnology sector continue expanding? Could Frequency diversify its offerings? Factors like these will boost the valuation of Frequency Therapeutics. Expected growth trajectory for Frequency significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Frequency Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Frequency Therapeutics requires distinguishing between market price and book value, where the latter reflects Frequency's accounting equity. The concept of intrinsic value - what Frequency Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Frequency Therapeutics' price substantially above or below its fundamental value.
Understanding that Frequency Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Frequency Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Frequency Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.